Drug Database
AN

anti-D immunoglobulin

✓ Approved

Kedrion · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-D immunoglobulin?

anti-D immunoglobulin is a polyclonal antibodies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyKedrion
Drug ClassPolyclonal Antibodies, Cell-based Therapies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

anti-D immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersRhesus haemolytic disease of newborn✓ Approved

Related Research Articles

PubMedCureus2026-08-30

Lethargy With Reversible Bilateral Basal Ganglia and Substantia Nigra Lesions in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report.

Abe Daisuke D, Hidaka Masaoki M, Kumamoto Masaya M, Kanazawa Yuka Y et al.

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a neuroinflammatory disorder characterized by a broad spectrum of neuropsychiatric symptoms, and the optimal treatment strategy for atypical or refractory cases has not been well established. We report the case of a 26-year-old woman with anti-NMDAR encephalitis associated with an ovarian teratoma who presented with acute psychiatric and neurological manifestations. The patient underwent tumor resection followed by first-line immunotherapies, including corticosteroids, intravenous immunoglobulin, and plasma exchange. Because of persistent neurological symptoms, second-line immunotherapy with cyclophosphamide was initiated, leading to gradual clinical improvement. However, she subsequently developed lethargy and upper-limb tremors, accompanied by bilateral basal ganglia and substantia nigra abnormalities on MRI. Notably, both her clinical symptoms and radiological abnormalities improved following an additional course of cyclophosphamide treatment. This report highlights a rare clinical and radiological manifestation and suggests that additional immunotherapy may be effective for delayed neurological worsening.

PMID 42668959
Read full article →
PubMedJournal of blood medicine2026-08-30

Clinical Outcomes of Rh(D)-Incompatible Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Retrospective Case Series with a Narrative Literature Review.

Liu Miaomiao M, Lin Min M, Fu Weijia W, Wang Ziwei Z et al.

Rh(D)-negative individuals are relatively rare in the Chinese population, and clinical experience with Rh(D)-incompatible allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains limited. Compared with ABO incompatibility, the immunohaematological consequences of Rh(D) mismatch in allo-HSCT are less well defined. Herein, we report a single-centre retrospective case series of four patients receiving Rh(D)-incompatible allo-HSCT at our institution, including two Rh(D)-negative recipients with Rh(D)-positive donors and two Rh(D)-positive recipients with Rh(D)-negative donors. We systematically evaluated post-transplant transfusion strategies, haematological recovery, anti-D alloantibody seroconversion, haemolysis or graft-versus-host disease (GVHD), and long-term survival outcomes. During a median follow-up of 36 months (range, 24-48 months), none of the patients developed detectable anti-D alloantibodies. Only one patient exhibited laboratory evidence of subclinical haemolysis responsive to low-dose prednisone, and another patient developed grade II acute gastrointestinal GVHD controlled by immunosuppressive agents. Nevertheless, all patients achieved sustained haematological engraftment without transplant-related mortalities. Combined with data from a narrative literature review, our single-centre observations are consistent with prior studies showing low risks of clinically significant haemolysis and anti-D alloimmunisation after Rh(D)-incompatible allo-HSCT. Rh(D) mismatch does not appear to be associated with severe transplant complications in our limited cohort, but these findings cannot be generalised broadly given the extremely small sample size. Rigorous peri-transplant transfusion management and regular post-transplant serological monitoring are still mandatory for Rh(D)-mismatched recipients.

PMID 42668990
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Intrathecal immunoglobulin administration for refractory viral central nervous system infection after allogeneic hematopoietic stem cell transplantation].

Matsuo Masaaki M, Kusakabe Shinsuke S, Kurashige Ryumei R, Fukushima Kentaro K et al.

Central nervous system (CNS) viral infections after allogeneic hematopoietic stem cell transplantation are associated with poor prognosis and have limited therapeutic options. We report three cases of refractory CNS viral infection treated by combination therapy with antiviral agents and intrathecal immunoglobulin administration. Case 1 involved cytomegalovirus encephalitis, Case 2 varicella zoster virus meningitis, and Case 3 human herpesvirus 6 encephalitis; all were resistant to antiviral agents. Two patients achieved viral DNA negativity in cerebrospinal fluid, and none experienced adverse events related to intrathecal injection. Although no intrathecal immunoglobulin products have been approved for use in Japan, our findings suggest that this treatment may be a viable option in selected refractory cases. Further studies are warranted to clarify the optimal agent, dosage, and schedule.

PMID 42669504
Read full article →
PubMedToxicology and applied pharmacology2026-08-30

ΔA146Ply exerts anti-triple-negative breast cancer effects by inducing ferroptosis via regulation of the CYP24A1-mediated calcitriol-vitamin D receptor pathway.

Yu Ye Y, Zhang Zhengkun Z, Wang Dingxue D, Bai Xin X et al.

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, typically associated with poor clinical outcomes. Recently, ferroptosis has emerged as a promising therapeutic target for TNBC. ΔA146Ply, a novel pneumolysin variant, has demonstrated potential as an anti-tumor agent; however, its role in regulating ferroptosis remains unclear. This study investigates whether ΔA146Ply exerts anti-TNBC effects by promoting ferroptosis via the CYP24A1-mediated Calcitriol/vitamin D receptor (VDR) pathway. Our in vitro results reveal that ΔA146Ply inhibits MDA-MB-231 cells by inducing ferroptosis. Mechanistically, we demonstrate that CYP24A1 negatively regulates the Calcitriol-VDR pathway and serves as a critical mediator of ferroptosis. In vivo, ΔA146Ply suppresses TNBC tumor growth by downregulating CYP24A1 and promoting ferroptosis. In conclusion, ΔA146Ply exerts anti-TNBC effects by activating ferroptosis through the regulation of the CYP24A1-mediated Calcitriol-VDR pathway.

PMID 42669384
Read full article →
PubMedJournal of multidisciplinary healthcare2026-08-30

Narrative Medicine in Pediatric anti‑NMDA Receptor Encephalitis: A Mixed‑methods Evaluation of Triadic Outcomes Among Children, Parents, and Healthcare Providers.

Zhou Xiaolin X, Chen Xuezhen X, Li Pinggan P, Luo Xiangyang X et al.

Pediatric anti-NMDAR encephalitis can cause severe disability and profound caregiver distress. Narrative medicine has been proposed as a humanistic intervention, but its impact across the complete caregiving triad of children, parents, and healthcare providers has not been systematically evaluated. This exploratory study aimed to assess the multidimensional impact of narrative medicine interventions in this setting. This retrospective mixed-methods study included five children with severe anti-NMDAR encephalitis (admission mRS ≥4), their mothers, two physicians, and six nurses. Narrative medicine interventions included daily bedside narrative attention, parallel chart writing, family conferences, nurse-led narrative communication, and weekly sharing sessions. Quantitative outcomes included child mRS, parental anxiety (SAS), depression (SDS), caregiver burden (ZBI), and provider empathy (IRI), burnout (NBS), and meaningful work (WAMI). Qualitative data from parallel charts, reflective writings, and family interviews were analyzed thematically. All five children showed favourable neurological improvement (median mRS: 5→1 at 6 months; p=0.039); three returned to school. Parental outcomes showed substantial improvements: SAS (42.8→23.4, p<0.001, d=9.7), SDS (54.8→27.4, p<0.001, d=6.5), and ZBI (59.6→29.6, p<0.001, d=3.4). Nurses (n=6) showed increased empathy (IRI: 63.7→78.0, p=0.003, d=1.9) and reduced burnout (NBS: 73.0→56.3, p=0.002, d=2.1); physicians showed parallel improvements. Thematic analysis identified three potential mechanisms: clinical narrative signals, a window of narrative intervention (weeks 2-4), and bidirectional healing. In this small, exploratory retrospective case series, narrative medicine interventions were temporally associated with favourable trends in neurological outcomes, parental psychological states, and provider well-being. The proposed concepts of clinical narrative signals, a window of narrative intervention, and bidirectional healing offer a preliminary framework for integrating narrative practices into pediatric neurocritical care. These findings are hypothesis-generating and warrant prospective investigation in larger controlled studies.

PMID 42668963
Read full article →
PubMedEuropean heart journal2026-08-30

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes.

Wang Yifan Y, Danchin Nicolas N, Simon Tabassome T, Zeller Marianne M et al.

Cardiogenic shock (CS) is the most dreadful complication of acute coronary syndromes (ACS). Endothelial dysfunction and vascular leakage are hallmarks of CS pathophysiology; however, biomarkers reflecting these early processes are lacking. The adrenomedullin (ADM) system-the inactive precursor glycine-extended ADM (ADM-Gly), the activating enzyme peptidylglycine α-amidating monooxygenase (PAM), and biologically active ADM (bio-ADM)-modulates vascular tone and permeability. This study investigated associations of ADM system components with CS and 1-year mortality risk after ACS. ADM-Gly, PAM, and bio-ADM were assessed in 4098 (Switzerland; SPUM-ACS) and 824 (France; FAST-MI) ACS patients without CS on admission. The primary endpoint was in-hospital CS; the secondary endpoint was 1-year mortality. Biomarker-outcome associations were analysed using multivariable-adjusted regression models, and the incremental predictive value beyond established risk scores was quantified. Higher ADM-Gly and bio-ADM, but not PAM, were associated with systemic inflammation and haemodynamic compromise. ADM-Gly and bio-ADM independently predicted CS risk in Switzerland (adjusted odds ratio [aOR] per log2 increase, 1.44, 95% confidence interval [CI] 1.22-1.71, P < .001 and aOR 1.37, 95% CI 1.10-1.70, P = .004) and France (adjusted risk ratio [RR] per log2 increase, 1.82, 95% CI 1.34-2.48, P < .001 and aRR 1.55, 95% CI 1.15-2.10, P = .004), and were associated with 1-year mortality risk (adjusted hazard ratio [aHR] per log2 increase, 1.33, 95% CI 1.09-1.61, P = .005 and aHR 1.46, 95% CI 1.15-1.86, P = .002). Addition of ADM-Gly and bio-ADM to the ORBI risk score improved its discrimination (Δ area under the receiver operating characteristic curve 0.02), reclassification (net reclassification improvement 0.229), and model fit (Δ Akaike information criterion -26.9), with consistent results in external validation. ADM-Gly and bio-ADM, but not PAM, independently predict in-hospital CS and 1-year mortality risk in initially stable patients with ACS and improve early risk stratification.

PMID 42668424
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-D immunoglobulin